VANCOUVER, British Columbia, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. ( CSE : ISOL ) ( OTCQB : ISOLF ) ( FSE: LB6A.F ) (the “Company” or “Isodiol”) , a global CBD innovator and market leader, announces that the amended filings of the Company’s annual financial statements for the fiscal year ended March 31, 2018, have been submitted to the BCSC.  

Upon approval from the BCSC, the Company will restate its most recent audited financial statements with updated disclosures related to its business acquisitions and anticipates its shares on the Canadian Securities exchange to resume trading shortly after.

The Company will also release its quarterly financials for the three months ended June 30, shortly after restating its most recent audited financial statements.

For more information on Isodiol, please visit www.isodiol.com  

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade pure, natural CBD and the industry leader in the manufacturing and development of CBD consumer products.

Isodiol is the pioneer of many firsts in the CBD industry, including the commercialization of 99%+ pure, natural isolated CBD, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018 .

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.

Join Us On Facebook : https://www.facebook.com/IsodiolInternationalInc/ Twitter: @Isodiolintlinc

ON BEHALF OF THE BOARD Marcos Agramont ,  CEO & Director

INVESTOR RELATIONS: Ir@isodiol.com www.isodiol.com

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.